The Use of Purified Clotting Factor Concentrates in Hemophilia
- 16 June 1989
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 261 (23), 3434-3438
- https://doi.org/10.1001/jama.1989.03420230088032
Abstract
Treatment of hemophilia, although greatly improved in recent years, continues to be problematic owing to infectious complications of blood product replacement therapy. This report examines the therapeutic options presently available for the treatment of hemophilia, focusing on the potential for repeated viral exposure to influence the progression of infectious disease, decreased risks of viral transmission with blood products produced using newer viral inactivation procedures, higher economic costs of newer blood products, and the current inadequate supply of blood products in the United States. (JAMA. 1989;261:3434-3438)Keywords
This publication has 17 references indexed in Scilit:
- VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATESThe Lancet, 1988
- An inducible transcription factor activates expression of human immunodeficiency virus in T cellsNature, 1987
- Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) DiseaseNew England Journal of Medicine, 1987
- Procedures for the inactivation of viruses in clotting factor concentratesAmerican Journal of Hematology, 1986
- Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.Journal of Clinical Investigation, 1985
- Coincidental Appearance of LAV/HTLV-III Antibodies in Hemophiliacs and the Onset of the AIDS EpidemicNew England Journal of Medicine, 1985
- ABSENCE OF ANTIBODIES TO AIDS VIRUS IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATEThe Lancet, 1985
- Socioeconomic Evaluation of a State-Funded Comprehensive Hemophilia-Care ProgramNew England Journal of Medicine, 1982
- Liver Biopsy in Hemophilia AAnnals of Internal Medicine, 1977
- A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitorsPublished by American Medical Association (AMA) ,1968